Keynote Speaker

Raghavan Venkat (Venkat in short) obtained his M.S. and Ph.D. degrees in Chemical Engineering at The Ohio State University and a Certificate in Business from the Wharton School at University of Pennsylvania. Venkat joined MedImmune / AstraZeneca in 2006 and has worked in the biopharmaceutical industry for more than 27 years across many roles at GSK, Lilly and AZ. Over his career, Venkat has led teams or directly contributed to the commercialization of more than 12 biologics medicines, including Vaxzevria and Evusheld developed in response to the COVID pandemic. Venkat has strong expertise in pharmaceutical process and product development, especially in biologics process development and manufacturing, with keen interest and strength in novel modalities.  At AstraZeneca, he currently leads the Biopharmaceutical Development function responsible for end-to-end CMC development of all biologics within the AZ pipeline.